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Histone deacetylase (HDAC) inhibitors are promising new
epi-drugs, but the presence of both class I and class II enzymes
in HDAC complexes precludes a detailed elucidation of the
individual HDAC functions. By using the class II-specific HDAC
inhibitor MC1568, we separated class I- and class II-dependent
effects and defined the roles of class II enzymes in
muscle differentiation in cultured cells and in vivo. MC1568
arrests myogenesis by (i) decreasing myocyte enhancer factor 2D
(MEF2D) expression, (ii) by stabilizing the HDAC4–HDAC3–
MEF2D complex, and (iii) paradoxically, by inhibiting
differentiation-induced MEF2D acetylation. In vivo MC1568
shows an apparent tissue-selective HDAC inhibition. In skeletal
muscle and heart, MC1568 inhibits the activity of HDAC4 and
HDAC5 without affecting HDAC3 activity, thereby leaving
MEF2–HDAC complexes in a repressed state. Our results suggest
that HDAC class II-selective inhibitors might have a therapeutic
potential for the treatment of muscle and heart diseases.
Keywords: differentiation; epigenetic drugs; HDAC inhibitor;
signal transduction
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INTRODUCTION
Growing evidence supports a therapeutic potential for histone
deacetylases (HDACs) against diseases such as cancer (Minucci &
Pelicci, 2006), neurodegenerative disorders or cardiac hyper-
trophy (Zhang et al, 2002; Chang et al, 2004; Vega et al, 2004;
Mejat et al, 2005; Yang & Gregoire, 2005; Trivedi et al, 2007). The 18
human HDACs are divided into four subsets: class I (1–3,8), class II
(4, 5, 7, 9 form the class IIa, whereas 6, 10 belong to class IIb),
class III that are referred to as sirtuins (SIRT1–7) and class IV
(HDAC 11). Class I, II and IV HDACs share common features such
as the dependence on zinc for their enzymatic activity, whereas
class III HDACs are NADþ-dependent. Although class I HDACs
are nuclear and believed to act predominantly at the chromatin
level, class II HDACs shuttle between the cytoplasm and
nucleus and target selected physiological programmes. Class IIa
HDACs compete, in a signal-responsive manner, with p300 for
direct binding to myocyte enhancer factor 2 (MEF2), inhibiting the
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776expression of MEF2-responsive genes. HDAC4 and HDAC5
are predominantly expressed in the heart, skeletal muscle and
brain, the same tissues that express the highest levels of MEF2.
MEF2 activates or represses myogenesis, depending on its inter-
actions with HDACs, through the MADS/MEF2 domains, thus
revealing a regulating role for chromatin modifiers in muscular
gene activation (Lu et al, 2000a). Gene ablation experiments
support the organ-specific function of class II HDACs; HDAC5 or
HDAC9 knockout leads to cardiac hypertrophy (Chang et al,2 0 0 4 ;
McKinsey & Olson, 2004, 2005) and HDAC4 null mice show
skeletal defects possibly linked to altered RUNX2 (runt-related
transcription factor 2) action (Vega et al, 2004). HDAC6 inhibition
stimulates tubulin acetylation and influences cell motility (Palazzo
et al, 2003; Zhang et al, 2003), but the role of HDAC6 in cellular
management of misfolded proteins (Kawaguchi et al, 2003) has also
been reported. Class II HDACs recruit corepressors and/or protein-
modifying enzymes that, in turn, inactivate transcription factors.
The diverse HDAC actions provide a strong rationale for analysing
their functions by using selective inhibitors. Here we provide a
comparative cell-biological analysis of pan (suberoyl anilide
hydroxamic acid; SAHA) and class II selective (MC1568) HDAC
inhibitors (Mai et al, 2005). We report that MC1568 blocks muscle
cell differentiation by a new repressive mechanism. We also show
that MC1568 acts in vivo repressing MEF2 function through a
non-enzymatic mechanism. These findings are discussed in view of
the therapeutic implications of selective HDAC inhibitors.
RESULTS
Cancer cells are not affected by HDAC class II inhibition
Although MC1568 (Fig 1A; Mai et al, 2005) blocks the cellular
activity of HDAC4 in vitro, no inhibition is seen with MS275,
which inhibits class I (1, 2 and, to a lesser extent, 3), with the
exception of HDAC8, or with valproic acid (VPA; Fig 1B left).
MC1568 was tested using in vitro HDAC assays with HDAC1, 2,
3, 4, 5 and 6 recombinant proteins on histone (Fig 1B right, C) and
non-histone substrates (Lahm et al, 2007; Fig 1D right). The results
show that MC1568 is a specific class II inhibitor. Note that
recombinant human HDACs, the purity of which was verified
(supplementary Fig 1A online), might still be missing further
crucial components or post-translational modifications relevant
for their function. Furthermore, the HDAC inhibition was
proportional to the incubation time (supplementary Fig 1B online;
data not shown). At the cellular level, MC1568 inhibited HDAC6
in both breast (ZR75.1) and haematological (U937) cancer cells,
as revealed by hyper-acetylation of a-tubulin (supplementary
Fig 2D,1G online). Although class I inhibitors block cell-cycle
progression by inducing p21CIP1/WAF1 and tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL)-mediated apoptosis
(Nebbioso et al, 2005), MC1568 failed to inhibit cell proliferation
to any significant extent (supplementary Fig 2A–C,E,F online and
supplementary Fig 3A–C online). Thus, the anticancer effects of
pan-HDAC inhibitors might be related to their class I inhibition.
However, synergistic effects owing to simultaneous class I and II
inhibition or antiproliferative effects of class II HDAC inhibitors
when used at higher concentrations cannot be excluded.
MC1568 induces MEF2 repressory complex stabilization
The observation that class IIa HDACs are active in a ternary
complex with HDAC3–SMRT (silencing mediator for retinoid and
thyroid hormone receptor)–NCOR (nuclear receptor co-repressor 1;
Fischle et al, 2002) has previously precluded analysis of the
individual roles of HDAC3 and class II HDACs; however,
MC1568 allowed us to distinguish between the class I and class II
effects. MC1568 blocked the induction of myogenin and
a-myosin heavy chain (aMHC) gene expression 48h after the
addition of differentiation medium (Fig 2A lanes 1–3); even when
added 24h after the induction of differentiation, the inhibitor still
blocked myogenin (Fig 2A lane 4). MEF2D induction (Lu et al,
2000a) was also repressed. HDAC4 levels were not affected
(Fig 2B lane 2, Fig 2C lane 4). Interestingly, analogues of MC1568
(supplementary Fig 4A online and refs therein), reported to be
inactive on class II HDACs and clearly inactive on recombinant
human HDAC4 (supplementary Fig 4 online), were unable to
repress myogenesis as shown by aMHC gene expression
(supplementary Fig 4B online), thus confirming the specificity of
the MC1568 effect and the relevance of enzymatic inhibition.
Furthermore, MEF2D immunoprecipitation revealed that its
acetylation (Fig 2C lanes 1 and 2) was inhibited by MC1568
(Fig 2C lane 4) and the concomitant release of co-precipitated
HDAC4 was blocked (Fig 2C lanes 2–4; see also Fig 2D).
Given that class II HDACs are inhibited in the presence
of MC1568 (Fig 1), this deacetylation must be due to the action
of HDAC class I. Indeed, co-immunoprecipitation experiments
corroborated that HDAC3 forms a complex with MEF2D, which is
disrupted on differentiation yet stabilized by MC1568 (Fig 2D).
Neither HDAC1 nor HDAC2 were found to be associated with
MEF2D (data not shown), indicating that MEF2D deacetylation is
HDAC3-mediated. Complexes immunoprecipitated with MEF2D
retained HDAC activity in the presence of MC1568, whereas
co-exposure to VPA abolished this activity (Fig 3A). Thus, HDAC3,
present in the MEF2D complex, is responsible for the maintenance
of HDAC activity in the presence of MC1568. Furthermore,
quantitative PCR chromatin immunoprecipitation (qPCR ChIP)
revealed that histone H3 acetylation at the MEF2D target gene
myogenin promoter is also inhibited by MC1568 (Fig 3B),
consistent with a model in which MEF2 deacetylation and/or
stabilization of the HDAC3–HDAC4–MEF2D complex are a
consequence of the treatment with MC1568. Accordingly, MEF2D
qPCR ChIP confirmed its presence on myogenin and muscle
creatine kinase (MCK) promoters during differentiation and its
absence during MC1568 co-incubation, whereas HDAC3 and
HDAC4 were absent in both conditions (Fig 3C and supplemen-
tary Fig 5A online). In addition, MyoD recruitment to responsive
promoters was altered by MC1568, as well as by its activity on
4REluc and 3xMEF2luc reports (supplementary Fig 5B,C online).
Our results reveal that the pharmacological block of class II HDACs
unexpectedly results in the deacetylation of MEF2 by HDAC3 and
stabilization of the inhibitory HDAC3–HDAC4–MEF2D complex,
thus blocking MEF2 target gene activation.
Tissue-selective activity of MC1568 in mice
We tested the HDAC inhibitory potential of MC1568 in CD1
(Crl:CD-1(ICR)) outbred mice. Administration of the 50mg/kg
dose every 2 days for a 10-day period did not result in detectable
liver toxicity, weight loss or behavioural abnormalities. Even after
a 6-h acute administration of MC1568, tubulin acetylation
increased in organs such as the kidney, spleen, muscle and heart.
No effects were observed in the stomach, ovary/uterus, lung or
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Fig 1 |Enzymatic inhibition of class specific histone deacetylase inhibitors. (A) The chemical structures of suberoyl anilide hydroxamic acid (SAHA),
MS275 and MC1568. (B) Left: cell-based histone deacetylase (HDAC)4 and HDAC1 assay with HDAC inhibitors (all used at 5mM, except valproic acid
(VPA), which was used at 1mM); right: in vitro HDAC4 and HDAC1 assay with HDAC inhibitors on histone substrate (all used at 5mM, except VPA,
which was used at 1mM). (C) In vitro HDAC2, 3, 5 and 6 assay with HDAC inhibitors (all used at 5mM, except VPA, which was used at 1mM on
histone substrate). (D) HDAC4 and HDAC6 assay on the substrate trifluoroacetyl-lysine and the specific HDAC6 substrate. DPM, distintegrations per
minute; IP, immunoprecipitation; RFU, rate fluorescence unit; rhHDAC, recombinant human histone deacetylase.
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778brain where tubulin was differently but constantly acetylated
(Fig 3D). The observations that the muscle and heart showed
different and reciprocal expression of HDAC4 and HDAC5
(Fig 3E), and that in both cases these HDACs formed complexes
with HDAC3 and MEF2D (Fig 3E bottom part) suggest that in vivo
the MC1568 might act in a similar manner to that in C2C12 cells
(Fig 3C). Although immunoprecipitation experiments carried out
using HDAC5 reveal a clear dose-dependent HDAC5 inhibition in
heart extracts from MC1568-treated mice (Fig 3F), MEF2D
immunoprecipitations from identical heart extracts show residual
HDAC activity that can be inhibited only by class I HDAC
inhibitors, thus revealing that in vivo the MEF2D complex also
retains class I HDAC-dependent deacetylase activity in the
presence of MC1568. Note that in this respect the myogenin
expression levels are altered by MC1568 administration in
a dose-dependent manner in vivo (supplementary Fig 4C online),
thus strongly suggesting a mechanism for (de)regulation of
myogenesis for MC1568.
DISCUSSION
We have shown that MC1568 (Mai et al, 2005; Butler &
Kozikowski, 2008; Itoh et al, 2008) acts at three distinct levels
to interfere with myogenic signalling (Fig 4). First, it blocks the
class II HDAC enzymatic activity, concomitantly stabilizing the
interaction of MEF2 with the HDAC4–NCOR–HDAC3 complex
(Fig 2C,D), without altering HDAC4 acetylation levels
(supplementary Fig 6 online). This sustains muscle-specific gene
suppression. Second, the stabilization of the HDAC4–MEF2D
complex indirectly stabilizes the association of HDAC3 with
MEF2 (Fig 2D lanes 3 and 9), thereby providing an enzymatically
active HDAC (Fig 3A). Our finding is fully compatible with the
observation that the HDAC catalytic domain mediates the
repression activity of the carboxy-terminal regions of class II
HDACs (Lu et al, 2000b), whereas the amino-terminal extensions
seem to repress transcription by recruiting class I HDACs and the
corepressor C-terminal binding protein (Zhang et al, 2001).
In support of this idea, the N-terminal region of class II HDACs
(in particular HDAC4) has been reported to be responsible for
MEF2 repression in a deacetylase-independent manner (Lomonte
et al, 2004). That inhibition of class II HDAC enzymatic activity
leads to MEF2D repression reveals that HDAC4 absence (Chen
et al, 2006; Potthoff et al, 2007) can have the opposite effect of
blocking its enzymatic activity. Third, inhibition of HDAC4 during
differentiation does not block MEF2D deacetylation (Fig 2C).
Indeed, HDAC4 might not function as a MEF2 deacetylase (Zhao
et al, 2005). HDAC3, present in the complex, is responsible for
MEF2D deacetylation, as its activity is not blocked by MC1568.
That HDAC3 is necessary for cardiac energy metabolism has
recently been confirmed in a study on a conditional HDAC3-null
allele (Montgomery et al, 2008). The inability to recruit
co-activators and the sustained activity of class I HDACs are
likely to account for the low histone H3 acetylation on MEF2
target chromatin (Fig 3B). Finally, MC1568 stabilization of
HDAC4–MEF2D binding might account for the absence of MEF2D
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779(Fig 3C) and MyoD (supplementary Fig 5B online) on responsive
promoters. The fact that the activatory role of MyoD on
myogenesis measured in transfection on two responsive reporters
is impaired by MC1568 (supplementary Fig 5C online) strongly
supports our hypothesis, not excluding the possibility that
additional mechanisms might still occur. In vivo MC1568 showed
organ-selective effects. The fact that MC1568 showed inhibitory
action on HDAC5 in vitro and in vivo (Fig 1, 3), and the data from
the mice heart and skeletal muscles confirm the mechanism
described in C2C12 cells (Fig 3; supplementary Fig 4C,5 online).
Recent studies have pointed to the possible use of HDAC
inhibitors in the treatment of cardiac hypertrophy (Antos et al,
2003; McKinsey & Olson, 2005; Trivedi et al, 2007). Interestingly,
class II HDACs function as signal-responsive repressors of cardiac
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780hypertrophy and heart failure, presumably through their ability to
block MEF2 target genes (Zhang et al, 2002). Therefore, class II-
specific HDAC inhibitors, which inhibit HDAC activity and
block MEF2-mediated transactivation, might represent new tools.
The challenge will be to ensure that sufficient MEF2 activity is
maintained for homoeostatic control in the heart, as MEF2
ablation leads to cardiomyopathy and an increased risk of
myocardial infarction in humans (Naya et al, 2002; Wang et al,
2003). Our results show new mechanisms by which HDAC class II
inhibition blocks myogenesis and demonstrate that HDAC class II
inhibition is fundamentally different from the inhibition of HDAC
expression. Future work will reveal the potential of class II
inhibitors in the treatment of cardiac diseases.
METHODS
Drugs. SAHA (MERCK, Readington, NJ, USA), MS275 (Schering
AG, Berlin-Wedding, Germany), MC1568 (Mai et al, 2005),
MC1617 and MC1757 were dissolved in dimethylsulphoxide
and used as indicated; VPA was purchased from SIGMA
(St Louis, MO, USA).
Cell lines. U937 and ZR75.1 were cultured using standard
procedures. C2C12 cells were cultured in DMEM supplemented
with 20% FCS (‘C2C12 growth medium’) or with 2% horse
serum (‘C2C12 differentiation medium’) and 50mg/ml penicillin-
streptomycin and 2mM glutamine.
Cell-based human HDAC1 and HDAC4 assay. Assays were
carried out as reported previously (Mai et al, 2005). Also see
supplementary information online.
Fluorimetric human recombinant HDAC1, 2, 3, 4, 5 and 6
assays. The HDAC assay was carried out according to the
supplier’s instructions (BIOMOL, Plymouth Meeting, PA, USA),
using the specific purified recombinant proteins. Also see
supplementary information online.
HDAC4 and HDAC6 assay on non-histone substrates. The assay
has been carried out as described in Lahm et al (2007) on the
trifluoroacetyl lysine substrate or on the HDAC6 selective
substrate (Heltweg et al, 2004). Cell-cycle differentiation and
apoptosis studies were carried out as described in Mai et al (2005,
2006) and Nebbioso et al (2005).
Antibodies. Antibodies against HDAC4, acetyl-tubuline and
tubulin were obtained from SIGMA and Abcam (Cambridge,
UK); HDAC1 and HDAC5 from Abcam; p21 and MEF2D from
Becton Dickinson (Franklin Lakes, NJ, USA); acetyl lysines from
Upstate (Bedford, MA, USA); myogenin, MHC, HSP70 and
HDAC3 from Santa Cruz (Santa Cruz, CA, USA) and Abcam.
Immunoprecipitation assay and coupling. See supplementary
information online.
C2C12 transfection experiments. See supplementary information
online.
Chromatin Immunoprecipitation assay. Acetyl H3 (Upstate), MEF2D
(Becton Dickinson), MyoD and purified IgG (Santa Cruz) were used.
ChIP assays were carried out as described in Nebbioso et al (2005) and
Denissov et al (2007). For details see supplementary information online.
Muscle differentiation assays. C2C12 cells were incubated with
growth (C) or differentiation medium (D) for 48h. C2C12 cells
were incubated with (D) and treated with MC1568 at both 0 and
24h after the starting of differentiation. Cells were collected at
48h and Western blots, IP or ChIP were carried out.
Mice treatment and tissue homogenization. See supplementary
information online.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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the MEF2–HDAC4 interaction, allowing association of a co-activator complex and target gene expression, as CREB (cyclic AMP response element
binding)-binding protein (CBP)/p300 and HDAC4 bindings to MEF2 are mutually exclusive. The miR-1 achieves the same effect by down regulating
HDAC4. HDAC inhibition does not result in the same events as the removal of HDAC4. Pan-histone decetylase inhibitors (HDACi) block both HDAC3
and HDAC4 and, depending on the stage of myogenesis, might block or stimulate differentiation. By contrast, MC1568 blocks HDAC4 activity but
enhances the HDAC4–MEF2 interaction, thus resulting in enforced repression. SAHA, suberoyl anilide hydroxamic acid; TSA, tricostatin A.
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